Literature DB >> 11567737

Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV.

H K Altes1, D A Price, V A Jansen.   

Abstract

Recent technological advances have revolutionised our capacity to induce cytotoxic T lymphocyte (CTL) responses with a variety of vaccine formulations and delivery systems. However, the conditions required for a CTL-inducing vaccine to provide protection from infection or disease are poorly understood, and the results of challenge experiments have not been consistent. Here we use a mathematical model to examine the requirements necessary for successful vaccination against human immunodeficiency virus (HIV) through cellular immunity. We describe the interaction between cytotoxic T cells and infected lymphocytes, capturing the essence of a persistent infection of immune cells. We conclude that to protect from infection, the cellular immune response should be boosted to levels exceeding those in chronic infection. This requires either that effector CTL exceed this threshold before infection, or that a memory CTL population is established that can yield this level of effector CTL very quickly upon infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567737     DOI: 10.1016/s0264-410x(01)00318-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.

Authors:  Tracey J Harvey; Itaru Anraku; Richard Linedale; David Harrich; Jason Mackenzie; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Occurrence of HIV eradication for preexposure prophylaxis treatment with a deterministic HIV model.

Authors:  Hyeygjeon Chang; Claude Moog; Alessandro Astolfi
Journal:  IET Syst Biol       Date:  2016-12       Impact factor: 1.615

3.  Kunjin replicon-based simian immunodeficiency virus gag vaccines.

Authors:  Itaru Anraku; Vladislav V Mokhonov; Paweena Rattanasena; Ekaterina I Mokhonova; Jason Leung; Gorben Pijlman; Andrea Cara; Wayne A Schroder; Alexander A Khromykh; Andreas Suhrbier
Journal:  Vaccine       Date:  2008-04-21       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.